Kodiak Sciences Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.14
- Today's High:
- $2.34
- Open Price:
- $2.22
- 52W Low:
- $2.03
- 52W High:
- $9.8
- Prev. Close:
- $2.22
- Volume:
- 763777
Company Statistics
- Market Cap.:
- $125.89 million
- Book Value:
- 6.479
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -28.53%
- Return on Equity TTM:
- -68.66%
Company Profile
Kodiak Sciences Inc had its IPO on 2018-10-04 under the ticker symbol KOD.
The company operates in the Healthcare sector and Biotechnology industry. Kodiak Sciences Inc has a staff strength of 118 employees.
Stock update
Shares of Kodiak Sciences Inc opened at $2.22 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.14 - $2.34, and closed at $2.17.
This is a -2.25% slip from the previous day's closing price.
A total volume of 763,777 shares were traded at the close of the day’s session.
In the last one week, shares of Kodiak Sciences Inc have slipped by -9.58%.
Kodiak Sciences Inc's Key Ratios
Kodiak Sciences Inc has a market cap of $125.89 million, indicating a price to book ratio of 0.7952 and a price to sales ratio of 0.
In the last 12-months Kodiak Sciences Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-301702016. The EBITDA ratio measures Kodiak Sciences Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Kodiak Sciences Inc’s operating margin was 0% while its return on assets stood at -28.53% with a return of equity of -68.66%.
In Q2, Kodiak Sciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Kodiak Sciences Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-6.08 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Kodiak Sciences Inc’s profitability.
Kodiak Sciences Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.1968. Its price to sales ratio in the trailing 12-months stood at 0.
Kodiak Sciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $589.66 million
- Total Liabilities
- $74.24 million
- Operating Cash Flow
- $103.84 million
- Capital Expenditure
- $1.47 million
- Dividend Payout Ratio
- 0%
Kodiak Sciences Inc ended 2024 with $589.66 million in total assets and $0 in total liabilities. Its intangible assets were valued at $589.66 million while shareholder equity stood at $-1043008000.00.
Kodiak Sciences Inc ended 2024 with $0 in deferred long-term liabilities, $74.24 million in other current liabilities, 5000.00 in common stock, $-1043008000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $378.67 million and cash and short-term investments were $378.67 million. The company’s total short-term debt was $7,851,000 while long-term debt stood at $0.
Kodiak Sciences Inc’s total current assets stands at $386.96 million while long-term investments were $0 and short-term investments were $0.00. Its net receivables were $0 compared to accounts payable of $12.35 million and inventory worth $0.
In 2024, Kodiak Sciences Inc's operating cash flow was $103.84 million while its capital expenditure stood at $1.47 million.
Comparatively, Kodiak Sciences Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2.17
- 52-Week High
- $9.8
- 52-Week Low
- $2.03
- Analyst Target Price
- $12.25
Kodiak Sciences Inc stock is currently trading at $2.17 per share. It touched a 52-week high of $9.8 and a 52-week low of $9.8. Analysts tracking the stock have a 12-month average target price of $12.25.
Its 50-day moving average was $3.92 and 200-day moving average was $5.97 The short ratio stood at 1.14 indicating a short percent outstanding of 0%.
Around 571.4% of the company’s stock are held by insiders while 7977% are held by institutions.
Frequently Asked Questions About Kodiak Sciences Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company’s preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.